Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Atglistatin 是脂肪甘油三酯脂酶的选择性抑制剂(IC50:0.7 μM),在体外具有抑制脂解的功能。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 265 | 现货 | ||
2 mg | ¥ 372 | 现货 | ||
5 mg | ¥ 663 | 现货 | ||
10 mg | ¥ 995 | 现货 | ||
25 mg | ¥ 1,870 | 现货 | ||
50 mg | ¥ 3,280 | 现货 | ||
100 mg | ¥ 4,780 | 现货 | ||
500 mg | ¥ 9,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 713 | 现货 |
产品描述 | Atglistatin is a highly effective, specific and competitive ATGL inhibitor with an IC50 of ~0.7 μM for inhibition of lipolysis in vitro, and no toxicity when the concentration up to 50 μM. |
靶点活性 | ATGL:0.7 μM |
体外活性 | Atglistatin可抑制ATGL,从而使细胞和器官培养中的脂类分解受到抑制,且浓度达50 μM时仍无细胞毒性。 |
体内活性 | Atglistatin(p.o.)剂量依赖性地减少FA和甘油,减少量分别高达50%和62%,也会显著减少血浆中TG水平(43%).在体内,Atglistatin(i.p.)剂量与时间依赖性地抑制脂类分解.此外,Atglistatin有明显的组织分布差异,主要在肝脏和脂肪组织中积累。 |
激酶实验 | Determination of lipase activity: For determination of lipase activity, lysates are incubated with a substrate containing radiolabeled [9,10-3H(N)]-triolein. Subsequently, FA are extracted and quantitated by liquid scintilation counting. Data are presented as mean S.D. of triplicate determinations and representative for at least three independent experiments. |
细胞实验 | For MTT-based in vitro viability assays, cells are seeded in 96-well plates and cultured under standard conditions for 24 h. The next day, cells are pretreated with different concentrations of Atglistatin dissolved in DMSO or Cisplatin dissolved in DMF as positive control for 2 h. Medium is replaced by an identical fresh medium and incubated again for the indicated time points. Thereafter, cells are incubated for 3 h with 100 μL Thiazolyl Blue Tetrazolium Bromide (MTT). The resulting violet formazan crystals are dissolved by adding 100 μL of MTT solubilization solution (0.1% NP-40, 4 mM HCl and anhydrous isopropanol). After complete dissolution of the formazan product, absorbance is measured at 595 nm using 690 nm as reference wavelength.(Only for Reference) |
分子量 | 283.37 |
分子式 | C17H21N3O |
CAS No. | 1469924-27-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 52 mg/mL (183.5 mM)
Ethanol: 4 mg/mL (14.11 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 3.529 mL | 17.6448 mL | 35.2896 mL | 88.2239 mL |
5 mM | 0.7058 mL | 3.529 mL | 7.0579 mL | 17.6448 mL | |
10 mM | 0.3529 mL | 1.7645 mL | 3.529 mL | 8.8224 mL | |
DMSO | 20 mM | 0.1764 mL | 0.8822 mL | 1.7645 mL | 4.4112 mL |
50 mM | 0.0706 mL | 0.3529 mL | 0.7058 mL | 1.7645 mL | |
100 mM | 0.0353 mL | 0.1764 mL | 0.3529 mL | 0.8822 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Atglistatin 1469924-27-3 Metabolism Lipase ATGL inhibit Adipose triglyceride lipase Inhibitor inhibitor